Abstract. Tenoxicam (TNX) is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, backache and pain. However, prolonged oral use of this drug is associated with gastrointestinal adverse events like peptic ulceration, thus necessitating its development as topical formulation that could obviate the adverse effects and improve patient compliance. The present study was aimed at development of microemulsion-based formulations of TNX for topical delivery at the affected site. The pseudoternary phase diagrams were developed and microemulsion formulations were prepared using Captex 300/oleic acid as oil, Tween 80 as surfactant and n-butanol/ethanol as co-surfactant. Optimized microemulsions were characterized for drug content, droplet size, viscosity, pH and zeta potential. The ex vivo permeation studies through Laca mice skin were performed using Franz diffusion cell assembly, and the permeation profile of the microemulsion formulation was compared with aqueous suspension of drug and drug incorporated in conventional cream. Microemulsion formulations of TNX showed significantly higher (p<0.001) mean cumulative percent permeation values in comparison to conventional cream and suspension of drug. In vivo anti-arthritic and anti-inflammatory activity of the developed TNX formulations was evaluated using various inflammatory models such as air pouch model, xylene-induced ear edema, cotton pellet granuloma and carrageenaninduced inflammation. Microemulsion formulations were found to be superior in controlling inflammation as compared to conventional topical dosage forms and showed efficacy equivalent to oral formulation. Results suggest that the developed microemulsion formulations may be used for effective topical delivery of TNX to treat various inflammatory conditions.
INTRODUCTION
Tenoxicam (TNX) is an analogue of a piroxicam and is used to relieve inflammation, swelling, stiffness and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, backache etc. It is commercially available in several dosage forms such as tablets, suppositories and injectables with each dosage form having its own limitation pertaining to patient compliance (1) .
Like other non-steroidal anti-inflammatory drugs (NSAIDs), oral administration of TNX shows gastrointestinal adverse effects with detrimental effects not only limited to the oesophagus and stomach but to the small intestine as well (2) . Moreover, the chronic oral use of NSAIDs has been found to increase the risk of peptic ulcer disease complications by 3-5-fold, and it has been estimated that 15-35% of all peptic ulcer complications is a consequence of prolonged NSAIDs use (3) . Therefore, topical administration of NSAIDs is becoming an important alternative to oral route of administration (4) . Administered topically, NSAIDs penetrate slowly and in small quantities into the systemic circulation; bioavailability and maximal plasma NSAID concentrations after topical application are generally less than 5 and 15%, respectively, compared with equivalent oral administration (5) . Common topical dosage forms for administration of NSAIDs include creams, gels and ointments. However, these primitive dosage forms suffer from inefficient percutaneous permeation through the human skin. This has lead to development of colloidal delivery systems such as liposomes, niosomes, microemulsions and solid lipid nanoparticles to improve drug permeation through the skin. In lieu of this, various novel dermal formulations of TNX has been explored in the recent years with development of transdermal films and proniosomal gel formulation (6, 7) .
Microemulsions are colloidal dispersions composed of oil phase, aqueous phase, surfactant and co-surfactant in appropriate ratios. These consist of single optically isotropic and thermodynamically stable system with a droplet diameter usually within the range of 10-100 nm (8) . Because of their structural components, microemulsions have become increasingly popular due to their high solubilization potential for both lipophilic and hydrophilic agents (9) . Their ability to reduce diffusional barrier of the stratum corneum coupled with superior thermodynamic stability help in effective cutaneous delivery of drugs. However, they possess low viscosity; therefore, gelling agents like Carbomer 940 and xanthan gum are generally added to make a suitable dosage form for topical application (10) 
l microemulsion-based formulations for dermal delivery of TNX and to investigate ex vivo permeation rate, antiarthritic and anti-inflammatory efficacy of different TNX preparations using various animal models of acute and chronic inflammation. Therapeutic efficacy of developed topical formulations was also compared with oral formulation.
MATERIALS AND METHODS
TNX was obtained as a gift sample from Cipla Ltd, Mumbai, India. Captex 200 and 300 were obtained as a gift sample from Abitech Corporation, USA. Oleic acid, isopropyl myristate (IPM), castor oil, Tween 20 and Tween 40 were procured from Loba Chemie Pvt. Ltd., Mumbai, India. Tween 60 and Tween 80 were purchased from S.D. Fine Chem Ltd., Mumbai, India. All the other chemicals used were of the analytical grade.
Animals
Male Laca mice (25-30 g ) and female Sprague-Dawley rats (200-250 g) bred at the Central Animal House (CAH) of Panjab University, Chandigarh, India, were used for the study. Animals were fed with a standard diet ad libitum and housed in a temperature-controlled room (25±2°C, 60-70% humidity), in accordance with the institution ethical committee regulations. Animals were acclimatized to laboratory conditions before the test.
Solubility Studies
Solubility studies of TNX were carried out in different oils (isopropyl myristate (IPM), castor oil, Captex 200, Captex 300 and oleic acid) and surfactants (Tween 20, Tween 40, Tween 60 and Tween 80), using the shake flask method of solubility determination (11) . Excess of drug was added to a fixed volume of each solvent (10 mL) in different flasks, which were kept at 37±0.5°C in a thermostatic water shaker bath for 24 h. The flasks were removed after 24 h, contents were filtered through a 0.45-μm filter, and filtrates were analyzed spectrophotometrically at 370 nm after appropriate dilution. Studies were carried out in triplicate (12) .
Selection of Microemulsion Components
Selection of oil was done based on solubility of TNX in oil. Further, surfactant was selected based on its emulsification ability. A 1:1 mixture of surfactant (Tween 80) and oil (Captex 300/oleic acid) was homogenized, and 50 mg of isotropic mixture was weighed and diluted with double-distilled water to 50 ml to give a fine emulsion. The emulsions were allowed to stand for 2 h and their transmittance was determined at 650 nm by UV spectrophotometer using double-distilled water as blank.
Titration method was used to find the appropriate cosurfactant (13) . The mixtures of surfactant and co-surfactant were made in predetermined weight ratios (K m ). Each surfactant and co-surfactant mixture was added to mixtures of oil and water in a dropwise manner under the mixing of magnetic stirrer, at room temperature. After each addition, the samples were stirred to reach the equilibrium (water/oil ratio was kept constant at 1:1). When a sufficient amount of the surfactant/ co-surfactant mixture (S/Cos) was added to completely solubilize the equal masses of oil and water (SCoS min ), a single phase microemulsion was formed. The transparent samples were allowed to equilibrate for minimum of 72 h.
Construction of Ternary Phase Diagrams
I n o r d e r t o a s ce r t a i n m i c r o e m u l s i o n r e g i o n , pseudoternary phase diagrams were constructed using the method of titration (14) . The mixture of oil (Captex 300/ oleic acid) and series of S/Cos mixtures were titrated with double-distilled water at room temperature under moderate magnetic stirring. After being equilibrated, the mixtures were assessed visually and determined as being microemulsions, emulsions or gels.
Preparation of Microemulsion Formulations
After identification of the microemulsion region in the phase diagram, TNX loaded o/w microemulsion (TNX 03 and 04) were prepared by dissolving TNX (0.15%) in Captex 300/ oleic acid. Subsequently, a mixture of surfactant (Tween 80) and co-surfactant (n-butanol/ethanol) was added to the oily phase under continuous magnetic stirring and appropriate amount of water was added dropwise, and a clear microemulsion was obtained spontaneously (Table I) . Finally, both the microemulsion formulations were gelled with Carbopol 940 in order to make them rheologically favourable for topical delivery.
Preparation of Conventional Cream and Suspension
TNX (0.15%) was formulated in a conventional cream (TNX 01) containing sorbitan mono-oleate (6%), white bees wax (3%), white soft paraffin (36%) and liquid paraffin (15%). TNX suspension (0.15%) (TNX 02) was prepared by dispersing TNX in 4% w/v sodium carboxymethylcellulose (CMC) dispersion in water.
Characterization of Microemulsions
Prepared microemulsion formulations were characterized for drug content, pH, droplet size, zeta potential and viscosity. Morphology and structure of the microstructures of drugloaded microemulsion was determined with the aid of transmission electron microscopy (TEM) (15) . Droplet size and size distribution were analyzed using laser light scattering technique (Malvern Zetasizer™).
T h e r h e o l o g i c a l b e h a v i o u r o f t h e p r e p a r e d microemulsion was determined with a DV-II viscometer (Brookfield, UK). The microemulsions were submitted to up and down cycles (0-100 rpm spindle rotation speed) at 32.0± 0.1°C, and the rheological behaviour was evaluated by plotting shear rate against shear stress (16) . The spreadability of the developed TNX formulations was evaluated using Texture Analyzer TM equipment, equipped with a 5-kg load cell to determine different rheological properties of prepared formulations viz., work of shear and stickiness.
Ex Vivo Skin Permeation Study
Male Laca mice skin (thickness 0.5-0.7 mm) previously shaved and washed with normal saline was mounted on Franz diffusion cell assembly with the stratum corneum facing donor compartment. The receptor compartment consisted of 30 mL phosphate buffer (pH 6.4 with 20% ethanol) maintained at 37 ±1°C and diffusional area of 2.84 cm 2 . TNX showed sufficient solubility (1.044±0.041 mg/ml) in this media. For ex vivo permeation studies, 1 g of formulation TNX 01/TNX 02/TNX 03/ TNX 04 containing 1.5 mg of TNX was applied on the skin in the donor compartment. An aliquot of 1-mL sample was withdrawn at suitable time intervals and replaced immediately with an equal volume of fresh diffusion medium (17) . The samples were analyzed spectrophotometrically at 370 nm after suitable dilutions. Similarly, permeation studies were performed using blank formulations without drug. Blank values were subtracted from test to account for any absorbance values due to leachants from the skin or formulation components. All experiments were performed in triplicate.
At the end of the permeation study, the skin mounted on the diffusion cell was removed carefully. The remaining formulation in the donor compartment adhering to the skin was scraped off. The above-mentioned cleaned skin was washed three to four times with distilled water. Subsequently, the skin was dipped in 5 ml methanol and kept overnight in a refrigerator (18) . Supernatant was filtered using a 0.45-μm filter, and the filtrate was analyzed spectrophotometrically at 370 nm for drug concentration after suitable dilution (19) . Each experiment was conducted in triplicate.
Histopathology of Skin
Laca mice were used in the study. The hair on the dorsal side of the mice was removed in a tail-to-head direction without damaging the skin. Microemulsion formulations without TNX were applied uniformly on the dorsal region and allowed to be kept in contact for 4 h. Subsequently, the animals were sacrificed by cervical dislocation, the dorsal area was cut and subcutaneous tissue was removed. Each specimen was then fixed in 10% buffered formalin, embedded in paraffin and microtome. The specimens were stained with haematoxylin and eosin and observed under a high-power light microscope (20) .
Thermodynamic Stability Studies
Thermodynamic stability of prepared microemulsion formulations was evaluated by a previously reported method (21) .
Heating-Cooling Cycle
Six cycles between refrigerator temperature 4 and 45°C with storage at each temperature for 48 h were studied.
Centrifugation
The formulations passed in previous step were centrifuged at 3500 rpm for 30 min.
Freeze-Thaw Cycle
Three freeze-thaw cycles between −20°C and +25°C with storage at each temperature for 48 h were done for the formulations.
Temperature Stress Studies
Microemulsion formulations were stored in sealed glass containers at 4, 25 and 40°C for 90 days. The stability of the microemulsions was checked periodically with respect to transparency, phase separation, colour change and drug content of TNX at three different temperature conditions.
PHARMACODYNAMIC EFFICACY Air Pouch Model for Evaluating Anti-Arthritic Activity
Anti-arthritic activity of TNX formulations was evaluated by air pouch formation in female rats (Sprague-Dawley) weighing 200-250 g each. Animals were divided into six groups of three rats each with each group receiving different treatment (control, TNX 01, TNX 02, TNX 03, TNX 04 and oral). Dorsal air pouch were prepared by subcutaneous injection of 10 ml of air through a sterile syringe. Three days after the first injection of air, the pouches were reinflated by injection of an additional 10 ml of air (22, 23) . On the sixth day, 1 mL of 1% carrageenan in saline was injected into the pouch. Different TNX formulations (0.15%) were topically applied twice daily. After 48 h, the animals were sacrificed with overdose of ether, their pouch were flushed with 1 mL of saline. The pouch fluid was collected and immediately cooled in ice and evaluated for pouch volume, granuloma tissue weight and number of white blood cells.
Xylene-Induced Ear Edema
The effect of the different TNX formulations on acute topical inflammation was evaluated by a xylene-induced ear edema in mice (24) . Adult male Laca mice weighing 25-30 g were divided into six groups of four animals each with each group receiving different treatment (control, TNX 01, TNX 02, TNX 03, TNX 04 and oral). Different TNX formulations (0.15%) were applied on the outer surface of the right ear. The control group received plain carbopol gel. After 30 min of administration of test formulations, topical inflammation was induced on the dorsal surface of the right ear by application of xylene (20 μl). One hour after induction of inflammation, the mice were killed by overdose of ether anaesthesia and both ears were removed. Circular sections (7 mm diameter) of both the right (treated) and left (untreated) ears were punched out using a borer, and weighed.
Edema was determined as the weight difference between the two plugs. The anti-inflammatory activity was evaluated as percent edema inhibition in the treated animals relative to control animals.
where control=difference in mean weight of the right ear plug of control animals and mean weight of the left ear plug of control animals; test=difference in mean weight of the right ear plug of treated animals and mean weight of the left ear plug of treated animals (25, 26) .
Cotton Pellet Granuloma Test in Rats
Chronic inflammation was evaluated using cotton pellet granuloma test in rats (27) . Adult female Sprague-Dawley rats weighing 250-300 g were divided in six groups of three rats each with each group receiving different treatment (control, TNX 01, TNX 02, TNX 03, TNX 04 and oral). The animals were anaesthetized with ether after shaving the fur, and subcutaneous tunnels were formed by a blunted forceps and 20 mg of sterile cotton pellets were inserted subcutaneously on the dorsal side, one in each axilla. On day 1, both conventional and novel TNX formulations (0.15%) were topically applied. The control group was kept devoid of any kind of treatment. Formulations were administered once daily for the next 7 days. On day 8, animals were sacrificed by overdose of ether. The pellets were dissected out, freed of tissue attachments and the wet weight of cotton pellets was determined. These were then dried in the oven overnight at 70°C and reweighed. The percent inhibition was expressed by comparing the mean weight in the test groups with that in the control.
Suppression of Carrageenan-Induced Inflammation
The anti-inflammatory activity was conducted on SpragueDawley rats against the carrageenan-induced rat paw edema (28) . The animals were divided into six groups consisting of three animals each with each group receiving different treatment (control, TNX 01, TNX 02, TNX 03, TNX 04 and oral). Different TNX formulations (0.15%) were applied topically half an hour prior to the administration of carrageenan. The control group received the same experimental handling as test group except that vehicle alone was applied topically. After 30 min, 0.05 ml of 1% carrageenan was injected into the right hind foot of each rat under the planter aponeurosis (29) . The volume of the paw of rats of control (V c ) and treated (V t ) groups at different intervals of time was measured by a plethysmograph. The percent inhibition of edema volume was calculated using the following formula (30) .
Statistical Evaluation of Data
All data was statistically analyzed by one-way analysis of variance (ANOVA). Results were quoted as significant where p<0.001.
RESULTS AND DISCUSSION

Screening of Components-Solubility Studies
From different oils screened, solubility of TNX was found to be maximum in oleic acid followed by Captex 300, Captex 200, isopropyl myristate and castor oil, respectively. Amongst the surfactants screened TNX showed maximum solubility in Tween 80 followed by Tween 60, 20 and 40, respectively (Table II) .
Phase Studies
In most cases, single-chain surfactants alone are unable to reduce the o/w interfacial tension sufficiently to form a microemulsion (31, 32) . Surfactants like Tweens require the presence of other surface active agents, also known as cosurfactants, to form microemulsions (33) . Addition of shorter chain co-surfactant gives positive curvature, thereby favouring formation o/w type microemulsion. Amongst all the surfactants screened, Tween 80 showed maximum % transmittance which demonstrated its ability to emulsify the selected oils. (Fig. 1) . 
Characterization of Prepared Microemulsion
The results of our study indicate development of successful microemulsion formulations of TNX with optimum characteristics. The drug content of selected formulations TNX 03 and TNX 04 was found to be 99.403±0.086 and 99.801±0.149, respectively. The pH of microemulsion formulations TNX 03 and TNX 04 was found to be 5.54 and 5.68, respectively. Viscosity of TNX 03 was 11,928.88 cp, whereas viscosity of TNX 04 was found to be 11,122.43 cp. TEM confirmed the spherical nature of droplets (Fig. 2) , and the average diameter of droplets was found to be 106 nm for TNX 03 and 122 nm for TNX 04. The small diameter of both formulations (Fig. 3) could be attributed to the effect of co-surfactant molecules which lower the fluidity and surface tension of the interfacial film, thereby decreasing the radius of nanodroplets (32) . Zeta potential of both microemulsion formulations was found to be near zero. This could be attributed to non-ionic nature of Tween 80 which does not impart any charge to the droplet, thus providing better stability to the microemulsion system. Both microemulsion formulations after gelling demonstrated pseudoplastic and shear-thinning behaviour. This pseudoplasticity results from a colloidal network structure that aligns itself in the direction of shear, thereby decreasing the viscosity as the shear rate increases (16) . The shear-thinning behaviour is usually preferred so that the applied skin systems would be stable at rest; nevertheless, upon application on the skin, the viscosity decreases and drug permeation is enhanced (34) . Rheological properties play important role in efficient performance of a topical formulation. Optimum rheological properties are imperative for uniform and easy application of topical formulation for better patient compliance. Different parameters studied included work of shear and stickiness. Work of shear for TNX 03 and TNX 04 was found to be 0.006 and 0.007 kg sec, respectively, and stickiness of −0.014 kg for TNX 03 and −0.016 kg for TNX 04, thereby suggesting non-stickiness and acceptable spreadability of formulations.
Ex Vivo Permeation Studies
The ex vivo permeation profiles of all TNX formulations through mice skin are shown in Fig. 4 . The cumulative amount of TNX permeated in 24 h from aqueous suspension (TNX 02) was only 7.31±0.63%, whereas permeation from conventional cream (TNX 01) was found to be 27.972±0.81%; and from microemulsions, still higher skin permeation of 64.647±0.97% (TNX 03) and 70.829±0.84% (TNX 04) was obtained. Similarly, flux values from microemulsion formulations TNX 03 and TNX 04 were found to be 16.100±0.26 and 12.167±0.11 μg/h/cm 2 , respectively, in comparison to flux values of 6.933±0.231 and 1.100 ± 0.100 μg/h/cm 2 depicted by TNX 01 and TNX 02, respectively. The results obtained are consistent with previous studies concurring the efficacy of microemulsion in dermal delivery of drugs (10) . The ability of microemulsions to reduce the interfacial tension between the skin and vehicle results in faster permeation. The presence of known permeation enhancer nbutanol in TNX 03 also explains its better permeation. The intercalation/partition of the short-chain n-alkanols like nbutanol into the intercellular lipids of the stratum corneum is believed to be a critical part of the mechanism of action of penetration enhancement, thus altering the diffusivity of the stratum corneum towards TNX (35, 36) . Amongst the two microemulsion formulations, better permeation shown by TNX 04 might be due to synergistic action of ethanol and oleic acid. The skin retention of TNX from both microemulsion formulations was superior and significantly higher (p<0.001) in comparison to conventional cream and aqueous suspension. TNX retention from TNX 03 was found to be 11.429±0.399%, which was 4.6 times when compared to TNX 01 (2.469±0.24%) and 11.5 times when compared to TNX 02 (0.988±0.18%). Whereas, TNX 04 showed skin retention of 13.551±0.25%, which was 5.5 times when compared to conventional cream TNX 01 and 13.7 times when compared to TNX 02. The high skin retention from microemulsions could be attributed to microdepot formed by them leading to higher skin retention of drug.
Histopathology
The histology of excised mice skin of control and mice treated with microemulsions (without TNX) after 4 h is shown in Fig. 5 . Both microemulsions did not show any effect on the microscopic structure of the skin and no pathological changes 
Stability
Physical appearance of microemulsion formulations after six heating-cooling cycles remained unchanged and the formulations maintained transparency. No phase separation was observed and formulation was found to be stable. Centrifugation at 3500 rpm for 30 min did not reveal any signs of phase separation or precipitation, indicating physical stability of microemulsion. Finally, both TNX 03 and TNX 04 were found to be resistant to freeze-thaw cycles in terms of transparency and phase separation.
Temperature Stress Studies
Stability studies data at the end of 90 days showed that selected microemulsion formulations were stable for drug content, pH and characteristics like viscosity, clarity and colour, thereby suggesting the long-term stability of prepared formulations.
ANTI-INFLAMMATORY EFFICACY
Anti-Arthritic Activity Using Air Pouch Model
Formation of an air pouch induces the proliferation of cells that stratify on the inner surface of the pouch to form a structure similar to the synovial (37) . Injection of carrageenan induces inflammation and the pouch serves as a reservoir of cells and mediators that can be easily measured in the fluid that accumulates locally and extent of inflammation being directly proportional to the volume of exudates (38) . As evident from results given in Table III, TNX 03 and TNX 04 showed significantly higher (p 0.001) anti-inflammatory efficacy as compared to TNX 01 and TNX 02. Mean granuloma tissue weight in the groups treated with conventional cream (TNX 01) and aqueous suspension (TNX 02) was found to be twice in comparison to group treated with microemulsion gels TNX 03 and TNX 04. Mean leukocyte count, another manifestation of inflammation was also significantly higher in groups treated with conventional dosage forms (Table III) . Visual examination of the inside of the air pouch revealed a highly intense erythema and inflammation in control group, whereas in groups treated with conventional dosage forms the Fig. 8 . Effect of different TNX formulations on carrageenan-induced paw edema in rats Fig. 9 . Effect of different TNX formulations on xylene-induced ear edema in mice intensity of erythema was less when compared to control group (Fig. 6a-c) . In comparison, the groups treated with microemulsions TNX 03 and TNX 04 and oral treatment group showed only very slight erythema (Fig. 6d-f) . Results suggest that microemulsions TNX 03 and TNX 04 were more effective than conventional topical formulations and showed efficacy comparable to oral dosage form.
Cotton Pellet Granuloma in Rats
The cotton pellet granuloma is a model of chronic inflammation, and dry weight has been shown to correlate with the amount of granulomatous tissue formed (39) . The method is robust and reproducible and the implanted pellet is capable of producing a large effect on the proliferate component of the inflammatory process (40) . The granuloma is characterized by the formation of a fibrous vascularized capsule containing fibroblast and mononuclear infiltrate cells. Decreased granuloma tissue formation, prevention of occurrence of the collagen fibres and suppression of mucopolysaccharides are indicators of the anti-proliferative effect of NSAIDs (41) . Daily topical application of the microemulsion formulations TNX 03 and TNX 04 significantly (p<0.001) inhibited granulomatous tissue formation, in comparison to TNX 01, TNX 02 and control (Fig. 7) . The data also demonstrated that the antiinflammatory activity of topical microemulsions (TNX 03 and TNX 04) was comparable to oral treatment. The high antiinflammatory efficacy depicted by microemulsion formulations could be attributed to their ability to permeate and deposit in the skin, thereby providing a means for better control of inflammatory response in comparison to conventional cream and suspension dosage forms.
Carrageenan-Induced Hind Paw Edema in Rats
Carrageenan is a sulphated cell wall polysaccharide found in certain red algae. Upon injection into rat paws, carrageenan provokes a local, acute inflammatory reaction, which is used for evaluating anti-inflammatory agents (42) . Treatment with microemulsion formulations TNX 03 and TNX 04 displayed significant (p<0.001) inhibition of edema, 64.54 and 67.89%, respectively, in comparison to 21.57 and 6.31% showed by TNX 01 and TNX 02 (Fig. 8) . The higher anti-inflammatory efficacy of TNX 03 and TNX 04 could be attributed to its ability to get retained in skin for longer duration, thus modulating superior anti-inflammatory response in comparison to conventional cream and suspension.
Ear Edema Induced by Xylene in Mice
Xylene causes instant irritation of the mouse ear, which leads to fluid accumulation and edema, characteristic of the acute inflammatory response (26) . The xylene-induced mouse ear edema method has certain advantages of having good predictive value for screening anti-inflammatory agents. Application of microemulsion formulations TNX 03 and TNX 04 significantly (p 0.001) inhibited xylene-induced ear edema as compared to TNX 01 and 02 (Fig. 9) . Interestingly, microemulsion formulations displayed better antiinflammatory efficacy than the oral treatment of drug. Possible explanation for this could be due to the quick and instant penetration of the microemulsion at the site of application, thereby proving better control over the acute inflammatory response.
CONCLUSION
In the present study, o/w microemulsion formulations for the dermal delivery of TNX were developed and characterized. Ex vivo permeation rate of both microemulsion formulations was significantly higher when compared to conventional topical formulations TNX 01 and TNX 02 (p<0.001). In addition to better permeation, microemulsion formulations elicited significant (p<0.001) anti-arthritic and anti-inflammatory efficacy in various animal models of arthritis and inflammation, and therapeutic response was comparable to oral formulation of drug. Moreover, histopathology studies revealed dermal safety of both microemulsion formulations. In conclusion, our study demonstrated that microemulsion formulations of TNX could be a potential alternative to oral formulation of drug.
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